Notch-1 inhibition by withaferin-A: A therapeutic target against colon carcinogenesis

Molecular Cancer Therapeutics

Volumn 9, Issue 1, 2010, Pages 202-210

  Koduru, Srinivas ^a   Kumar, Raj ^a   Srinivasan, Sowmyalakshmi ^a   Evers, Mark B ^b,c   Damodaran, Chendil ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; S6 KINASE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WITHANIA SOMNIFERA;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; ERGOSTEROL; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTOR, NOTCH1;

EID: 73949113574     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0771     Document Type: Article

References (50)

1. Katoh M. Notch signaling in gastrointestinal tract (review). Int J Oncol 2007;30:247-51.
2. Leow CC, Romero MS, Ross S, Polakis P, Gao WQ. Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. Cancer Res 2004;64:6050-7.
3. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006;107:2223-33.
4. Li JL, Harris AL. Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell 2005;8:1-3.
5. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998;393:382-6.
6. Mumm JS, Schroeter EH, Saxena MT, et al. A ligand-induced extracellular cleavage regulates γ-secretase-like proteolytic activation of Notch1. Mol Cell 2000;5:197-206.
7. Rodilla V, Villanueva A, Obrador-Hevia A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A 2009;106:6315-20.
8. Chen F, Hasegawa H, Schmitt-Ulms G, et al. TMP21 is a presenilin complex component that modulates [γ]-secretase but not [epsiv]-secretase activity. Nature 2006;440:1208-12.
9. Kaether C, Haass C, Steiner H. Assembly, trafficking and function of γ-secretase. Neurodegener Dis 2006;3:275-83.
10. Bhanot U, Kohntop R, Hasel C, Moller P. Evidence of Notch pathway activation in the ectatic ducts of chronic pancreatitis. J Pathol 2008; 214:312-9.
11. Ehebauer M, Hayward P, Arias AM. Notch, a universal arbiter of cell fate decisions. Science 2006;314:1414-5.
12. Espinosa L, Santos S, Ingles-Esteve J, Munoz-Canoves P, Bigas A. p65-NF{κ}B synergizes with Notch to activate transcription by triggering cytoplasmic translocation of the nuclear receptor corepressor N-CoR. J Cell Sci 2002;115:1295-303.
13. Wang Z, Banerjee S, Li Y, Rahman KMW, Zhang Y, Sarkar FH. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-{κ}B, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006;66: 2778-84.
14. Rasool M, Varalakshmi P. Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: an in vivo and in vitro study. Vascul Pharmacol 2006;44:406-10.
15. Stan SD, Hahm E-R, Warin R, Singh SV. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 2008;68:7661-9.
16. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 2005;128:1354-68.
17. Baliga R, Zhang Z, Shah SV. Role of cytochrome P-450 in hydrogen peroxide-induced cytotoxicity to LLC-PK1 cells. Kidney Int 1996;50: 1118-24.
18. Koduru S, Sowmyalakshmi S, Kumar R, Gomathinayagam R, Rohr J, Damodaran C. Identification of a potent herbal molecule for the treatment of breast cancer. BMC Cancer 2009;9:41.
19. Lucio Miele BO. Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol 1999;181:393-409.
20. Liu ZJ, Xiao M, Balint K, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 2006;66:4182-90.
21. Shant J, Cheng K, Marasa BS, Wang J-Y, Raufman J-P. Akt-dependent NF-[κ]B activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res 2009;315:432-50.
22. Hwee-Luan A, Vinay T. Notch and NFκB signaling pathways: Do they collaborate in normal vertebrate brain development and function? BioEssays 2007;29:1039-47.
23. Androutsellis-Theotokis A, Leker RR, Soldner F, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442:823-6.
24. Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal 2009;21: 656-64.
25. Kim JW, Kim MJ, Kim KJ, et al. Notch interferes with the scaffold function of JNK-interacting protein 1 to inhibit the JNK signaling pathway. Proc Natl Acad Sci U S A 2005;102:14308-13.
26. Kondoh K, Sunadome K, Nishida E. Notch Signaling Suppresses p38 MAPK Activity via Induction of MKP-1 in Myogenesis. J Biol Chem 2007;282:3058-65.
27. Veenendaal LM, Kranenburg O, Smakman N, Klomp A, Borel Rinkes IH, van Diest PJ. Differential Notch and TGFβ signaling in primary colorectal tumors and their corresponding metastases. Cell Oncol 2008;30:1-11.
28. Chu D, Wang W, Xie H, et al. Notch1 expression in colorectal carcinoma determines tumor differentiation status. J Gastrointest Surg 2009;13:253-60.
29. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE. γ secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005;24: 6333-44.
30. Fan X, Mikolaenko I, Elhassan I, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004; 64:7787-93.
31. Farnie G, Clarke RB, Spence K, et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007;99:616-27.
32. Meng RD, Shelton CC, Li Y-M, et al. {γ}-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 2009;69:573-82.
33. Weng AP, Nam Y, Wolfe MS, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003;23:655-64.
34. Akiyoshi T, Nakamura M, Yanai K, et al. γ-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology 2008;134:131-44.
35. Rychahou PG, Kang J, Gulhati P, et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A 2008;105:20315-20.
36. Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP, Brennan K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res 2009;69:5015-22.
37. Jones DR, Broad RM, Madrid LV, Baldwin AS, Jr., Mayo MW. Inhibition of NF-κB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann Thorac Surg 2000;70:930-6, discussion 6-7.
38. Oswald F, Liptay S, Adler G, Schmid RM. NF-κB2 is a putative target gene of activated Notch-1 via RBP-Jκ. Mol Cell Biol 1998;18:2077-88.
39. Kaileh M, Vanden Berghe W, Heyerick A, et al. Withaferin a strongly elicits IκB kinase β hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 2007;282: 4253-64.
40. Dan HC, Adli M, Baldwin AS. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I κ B kinase α. Cancer Res 2007;67:6263-9.
41. Lee DF, Kuo HP, Chen CT, et al. IKK β suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007;130:440-55.
42. Khoshnan A, Tindell C, Laux I, Bae D, Bennett B, Nel AE. The NF-κB cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 2000;165:1743-54.
43. Fennell DA. Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer. Clin Lung Cancer 2003;4:307-13.
44. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002;97:584-92.
45. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007;110:278-86.
46. Cheng Z, Guo X, Yang X, et al. PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res 2008;27:87.
47. Liu T, Yacoub R, Graham T, Yang L, Tighiouart M, O'Regan RM. Effect of mTOR inhibition on sensitivity of triple-negative breast cancer cells to epidermal growth factor inhibition. J Clin Oncol (Meeting Abstracts) 2009;27:1055.
48. Cullion K, Draheim KM, Hermance N, et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009;113: 6172-81.
49. Sowmyalakshmi S, Srinivas K, Raj K, Guhan V, Natasha K, Chendil D. Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. Int J Cancer 2009;125:961-7.
50. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298: 1911-2.